Market revenue in 2020 | USD 92.1 million |
Market revenue in 2028 | USD 239.3 million |
Growth rate | 12.7% (CAGR from 2020 to 2028) |
Largest segment | Lymphoma |
Fastest growing segment | Lymphoma |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 45.82% in 2020. Horizon Databook has segmented the Brazil hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
Brazil is expected to account for the largest share in the Latin America market and is anticipated to maintain its dominance over the forecast period. The large market can be attributed to increased access to testing kits in the market, high awareness as compared with other Latin American countries, and local presence of major market players.
Furthermore, increasing initiatives by several organizations such as the Brazilian Association of Lymphoma and Leukemia (ABRALE) to increase awareness about early diagnosis and treatment of diseases is expected to support the market growth.
In addition to this, increasing prevalence of hemato oncology cases will further drive the market growth in the review period. According to data published by Globocan 2020, around 11,396 new cases of leukemia, 11,445 new cases of non-Hodgkin lymphoma, and 3,254 new cases of Hodgkin lymphoma were estimated to be diagnosed in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account